Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22912507 | 0.86 | TDP1 (0.51) | ALDH1A1HSD17B10TDP1KDM4EPKM | |
| SCHEMBL8537744 | 0.86 | ALDH1A1 (0.44) | ALDH1A1TDP1KDM4EPKML3MBTL1 | |
| SCHEMBL9694340 | 0.84 | KDM4E (0.49) | ALDH1A1HSD17B10TDP1KDM4EL3MBTL1 | |
| SCHEMBL6017355 | 0.82 | TDP1 (0.54) | ALDH1A1HSD17B10TDP1KDM4EPKM | |
| SCHEMBL28630876 | 0.82 | ALDH1A1 (0.48) | ALDH1A1HSD17B10TDP1KDM4EPKM | |
| SCHEMBL4556786 | 0.81 | TDP1 (0.53) | ALDH1A1HSD17B10TDP1KDM4EPKM | |
| SCHEMBL4074618 | 0.81 | TDP1 (0.53) | ALDH1A1HSD17B10TDP1KDM4EPKM | |
| SCHEMBL29361610 | 0.81 | TDP1 (0.53) | ALDH1A1HSD17B10TDP1KDM4EPKM | |
| SCHEMBL30798461 | 0.81 | TDP1 (0.53) | ALDH1A1HSD17B10TDP1KDM4EPKM | |
| SCHEMBL16790454 | 0.80 | TDP1 (0.51) | ALDH1A1HSD17B10TDP1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103454-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20230159507-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159507-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159507-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11548880-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548880-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4046988-A1 | 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4046988-A1 | 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-3880654-B1 | 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3880654-B1 | 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20200157085-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200157085-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-05-21 | — | — | US | disclosed |
| EP-0277661-B1 | IMIDAZOPYRROLOPYRIDINES AND CONDENSED DERIVATIVES THEREOF USEFUL IN THE PREPARATION OF HERBICIDAL COMPOUNDS | AMERICAN CYANAMID COMPANY (US) | 1992-09-16 | — | — | EP | disclosed |
| EP-0133309-B1 | HERBICIDES AND METHOD FOR THE PREPARATION THEREOF | AMERICAN CYANAMID COMPANY (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0133310-B1 | IMIDAZOLIDINONES, AND IMIDAZOLIDINETHIONES, PROCESS FOR THE PREPARATION THEREOF, AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | AMERICAN CYANAMID COMPANY (US) | 1988-09-14 | — | — | EP | disclosed |
| EP-0277661-A1 | Imidazopyrrolopyridines and condensed derivatives thereof useful in the preparation of herbicidal compounds | AMERICAN CYANAMID COMPANY (US) | 1988-08-10 | — | — | EP | disclosed |
| US-4701208-A | Dihydroimidazopyrrolopyridine, quinoline, thieno- and furo[2,3-b]pyridine, dihydrothieno- and furo[2,3-b]-pyridine, thieno- and furo[3,2-b]pyridine and dihydrothieno- and furo[3,2-b]pyridine herbicides and method for preparation thereof | AMERICAN CYANAMID COMPANY (US) | 1987-10-20 | — | — | US | disclosed |
| US-4608079-A | Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1986-08-26 | — | — | US | disclosed |
| EP-0133310-A1 | Imidazolidinones, and imidazolidinethiones, process for the preparation thereof, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1985-02-20 | — | — | EP | disclosed |
| EP-0133309-A1 | Herbicides and method for the preparation thereof | AMERICAN CYANAMID COMPANY (US) | 1985-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157085-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | ALDH1A1 3168/4885HSD17B10 1678/4885TDP1 3819/4885 |
| US-20230159507-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | ALDH1A1 3168/4885HSD17B10 1678/4885TDP1 3819/4885 |
| US-20260103454-A1 | MODULATORS OF HEMOGLOBIN | HBZ, HBB, HBG2 | ALDH1A1 1843/4885HSD17B10 1736/4885TDP1 3514/4885 |
| US-11548880-B2 | Modulators of hemoglobin | HBG1, HBG2, HBB | ALDH1A1 3168/4885HSD17B10 1678/4885TDP1 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.